An anticipation that Dedicated Phase I, by utilizing QTinno apart from its existing infrastructure, will be able to deliver the full range of TQT/QTc studies thus becoming a turnkey provider of these studies to its customers.

Jason Bonanza, President and CEO of Dedicated Phase I, commented, We are excited to add NewCardio’s QTinno solution to our advanced Core ECG laboratory. By integrating this important technological advancement with our existing solutions, we can deliver TQT/QTc studies for upload to the FDA digital ECG warehouse with greater accuracy and lower intrinsic variability than the legacy manual or semi-automated methodologies provide. In addition, we can reduce study timelines by several weeks, providing significant savings to customers on the overall cost of the study. The net result is that sponsors will receive higher quality study results and also save time and money. This is a win-win for Dedicated Phase I and our customers.

This agreement will enable Dedicated Phase I to deliver quality TQT/QTc studies to its customers, to include both CROs and sponsors, with higher accuracy and lower variability in a more timely and cost-effective manner, said Vincent Renz, NewCardio’s President and Chief Operating Officer. Dedicated Phase I is truly an innovative organization, and this agreement demonstrates the firm’s commitment to the use of technology to improve quality and efficiency.

This Master Services Agreement is part of a transition from semi-automated methods to higher quality, more advanced and more efficient methodologies made possible for the first time through the use of QTinno solution.

The company’s innovative 3D ECG platform technology improves the accuracy and increases the diagnostic value of the standard 12-lead electrocardiogram (ECG). The company’s lead product is Qtinno. It is a software suite which provides an automated, comprehensive analysis of QT intervals and other ECG-based cardiac safety for the drug regulators and pharmaceutical industry. The Company believes that its QTinno software-based, analytical technology is a solution for reliable automated analysis of ECGs used to determine cardiac toxicity during drug development.